Inhalation Home

The only technical publication devoted exclusively to readers involved in development
and production of orally inhaled and nasal delivered pharmaceuticals.

Slide background
Slide background
Slide background

Article Archive

Browse by Subject Browse by Organization Browse by Author
Slide background
Slide background
Slide background


Inhalation 1-2-3
Cross Industry Organizations
Tablets & Capsules
INH Magazine

Cover Photo Courtesy of
Inhalation Sciences

Download Table of Contents

This Month’s Focus: Product Development/
Contract Testing

Accelerating inhalation product development: Choosing between outsourcing and developing internal capabilities

Examples of challenges in inhalation pharmaceutical development, how they were diagnosed and steps taken to improve confidence in the execution of outsourced studies. Where a long-term workload was expected, functions were brought in-house. Other activities were outsourced, with training provided for the contract research organizations.

A clinically relevant approach to assess in vitro bioequivalence for regulatory approval of DPIs: A case study

A clinically more relevant approach for comparing the aerodynamic particle size distribution (APSD) of a generic dry powder inhaler (DPI) to that of an originator has been proposed, which could potentially replace an EU standard. This article describes the results of a study that follows these principles for APSD in vitro bioequivalence (IVBE) assessment of three tiotropium DPIs.

General Features

Back Page: The EFA’s Active Asthma and COPD Patients ACCESS Care Report

The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is an alliance of 42 allergy, asthma and COPD patients’ organizations in 25 European countries. It has published a study of current limitations in access to healthcare for asthma and COPD patients to inform stakeholders so initiatives can be taken to fill existing and persisting gaps.

IPAC-RS: An update on recent activities

In 2019, the Consortium engaged with regulatory and standard-setting authorities, identified and publicized the OINDP industry’s positions on key issues of regulatory science and provided a forum for member discussions. This article also previews activities for 2020.

Previewing the Inhalation & Respiratory Drug Delivery USA Congress

The 3rd Annual Inhalation & Respiratory Drug Delivery USA Congress will be held in San Diego, California, US, March 17-18, 2020. The event will be co-located with the 3rd Annual Formulation & Drug Delivery USA Congress.

A preview of Respiratory Drug Delivery (RDD®) 2020

Respiratory Drug Delivery (RDD®) 2020 will take place April 26-30 and be immediately followed by a symposium jointly presented by RDD and the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS).

Previewing the IPAC-RS/RDD® Symposium

Respiratory Drug Delivery (RDD®) and IPAC-RS will jointly present the symposium, “The Global Regulatory Landscape and Advances in Digital Technology: Transforming the OINDP-Patient Experience.” The event will begin the afternoon of April 30 and continue on May 1 at the JW Marriott Desert Springs.

April Content

New insights into pMDI design using synchrotron radiation

The liability of fine particle dose as a single quality control metric

Cross-industry organizations: An update from ISAM

Back Page: Tree management to reduce allergens and ozone depletion

And more….

Issue Focuses

January: Reference and Buyer’s Resource

February: Product Development/ Contract Testing

April: Instruments

June: Nasal Delivery/Nebulizers

August: Particle Characterization

October: Devices

December: Quality/Compliance

Contact the editor:
Vicki Schuman
1155 Northland Drive
St. Paul, MN 55120
651-287-5600
Fax 651-287-5650
vschuman@cscpub.com

Inhalation Article Guidelines

Technical article requirements

The article should be technical and educational, but not promotional. It must be new, not previously published and must be at least 50% different from your previous articles or other articles you are simultaneously developing on the same subject.

All discussions of products or technologies must be in an unbiased, non-promotional, educational manner. If your article discusses products that have been commercialized or are in development, please be aware of the following: Inhalation takes a very limited approach in discussing products, usually listing only product name, delivered drug name and company name, unless a description is provided by the particular company that owns a product, such as in a case study article or product news release. In that way, each company can choose the information it wishes to discuss or disclose about its own products, rather than being discussed by an outside party with no ability to comment prior to publication. However, if an article is a case study, presentation of a novel technology or news article written by the owner company or its representative such as a scientist or consultant, we are happy to consider all information or data they wish to disclose, provided it is presented in a fair-balanced manner. Also, please avoid discussing product or development costs and do not make cost comparisons.

The article should be 2,500-3,500 words and must include at least five references or items for recommended reading.

We encourage images and/or data tables and have space for three or four of them. We’re flexible about that number so let us know if you need more image space. We also like to publish an additional photo or illustration at the beginning of the article. Images should be sent as separate files that meet the following specifications: high resolution, 300 dpi at a size of 7 x 7 inches and in only JPG, TIF or EPS formats.

Please be aware, due to copyrights, if you use figures or tables from articles that have been previously published in other journals, you must obtain permission from those journals in order to use the images. If you are an author on the published article in question, you may still need permission but there should be no fees from the other journal. If you are not an author and the other journal wants to charge you fees for usage, please contact us before proceeding. We do not want authors incurring costs in order to publish in Inhalation and there may be alternate approaches to citing information that could be used. Also, “open journals” do not charge for image use. If you have any questions or concerns, please contact us.

Editorial board review and production

All of our articles are peer-reviewed and must be accepted by our editorial board or a designated reviewer in order to be published. When you send us the article, it will go to a member of the board and we will coordinate communication between you. Once an article is accepted, we handle production and you will see the final article in layout before it goes to print or is published in the digital edition.

2020
Focus
Special Sections
January
Reference & Buyer’s Resource
February
Product Development/
Contract Testing
Formulation Development/
Excipients
April
Instruments
Education
June
Nasal Delivery/Nebulizers
Filling/Packaging
August
Particle Characterization
Particle Manufacturing
October
Devices
Outsourcing Services
December
Quality/Compliance
Capsules/Blisters
Slide background
Slide background
Buyers Guide